

Sentinel Oncology: A Small Molecule Oncology Drug Discovery Company

- Sentinel Oncology is a small molecule drug discovery company focusing on the discovery of new chemical entities for the treatment of cancer.
- Sentinel Oncology is seeking partners to out-license products from its oncology pipeline at the pre-clinical development phase.
- The company was founded in 2005 and has raised more than £2m in funding during the past two years. The company is located on the Cambridge Science Park, Cambridge, UK


Executive Management

Bob Boyle *Exec. Director*
Stuart Travers *Exec. Director*

Board of Directors

Bob Boyle *Sentinel Oncology*
Stuart Travers *Sentinel Oncology*
Ashok Venkitaraman *University of Cambridge*
Geraldine Rodgers *Cambridge Enterprise*
Gavin Simpson *Omnipartners LLP*

Product Pipeline



About Sentinel

Sentinel Oncology brings together a management team with over 70 years experience in the pharmaceutical and biotech sectors, a highly experienced and respected scientific advisory board chaired by Professor Ashok Venkitaraman, a world leader in DNA repair pathway research and a board of directors with a broad range of skills and a track record of success in the sector.

Pipeline

The Sentinel Oncology pipeline contains several novel small molecule programs designed to target DNA repair pathways, tumour hypoxia and both in combination:

- Hypoxia represents an important chemical environment within solid tumours and Sentinel has developed a range of lead molecules designed to deliver their effect only within these regions. These **Hypoxic Activated Inhibitors** represent a novel, first in class and highly attractive drug discovery opportunity.

- The **Targeted Synergy** program has generated drug molecules that deliver two synergistic therapeutic activities to solid tumours – a DNA damaging event **and** an inhibitor of key DNA repair enzymes leading to increased efficacy and therapeutic index.
- The Checkpoint 1 kinase program has led to the discovery of selective inhibitors with *in-vivo* efficacy. This target plays a key role in the maintenance of DNA repair mechanisms.
- The Flt 3/4 program has lead molecules with exquisite selectivity for the target kinases.
- PARP1 is a target important for the control of tumour growth through inhibition of DNA repair. Sentinel has collaborated with Prof Venkitaraman to discover potent and selective inhibitors ready for *in-vivo* evaluation.

Licensing

To discuss partnering opportunities or to arrange a meeting, please contact Stuart Travers. (stuart.travers@sentineloncology.com)